Mostrar el registro sencillo del ítem
dc.contributor.author | González Valdivieso, Juan | |
dc.contributor.author | Borrego, Belén | |
dc.contributor.author | Girotti ., Alessandra | |
dc.contributor.author | Moreno, Sandra | |
dc.contributor.author | Brun, Alejandro | |
dc.contributor.author | Bermejo Martín, Jesús Francisco | |
dc.contributor.author | Arias Vallejo, Francisco Javier | |
dc.date.accessioned | 2025-01-15T10:43:45Z | |
dc.date.available | 2025-01-15T10:43:45Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Molecular Pharmaceutics, 2020, vol. 17, n. 5, p. 1608-1620 | es |
dc.identifier.issn | 1543-8384 | es |
dc.identifier.uri | https://uvadoc.uva.es/handle/10324/73862 | |
dc.description | Producción Científica | es |
dc.description.abstract | This work analyzes the immunogenicity of six genetically engineered constructs based on elastin-like recombinamers (ELRs) fused to the Gn glycoprotein from Rift Valley fever virus (RVFV). Upon transfection, all constructs showed no effect on cell viability. While fusion constructs including ELR blocks containing hydrophobic amino acids (alanine or isoleucine) did not increase the expression of viral Gn in eukaryotic cells, glutamic acid- or valine-rich fusion proteins showed enhanced expression levels compared with the constructs encoding the viral antigen alone. However, in vivo DNA plasmid immunization assays determined that the more hydrophobic constructs reduced viremia levels after RVFV challenge to a higher extent than glutamic- or valine-rich encoding plasmids and were better inducers of cellular immunity as judged by in vitro restimulation experiments. Although the Gn-ELR fusion constructs did not surpass the protective efficacy of a plasmid vaccine expressing nonfused Gn, our results warrant further experiments directed to take advantage of the immunomodulatory potential of ELR biomaterials for improving vaccines against infectious diseases. | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | American Chemical Society | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.classification | Rift Valley fever virus | es |
dc.subject.classification | DNA vaccines | es |
dc.subject.classification | elastin-like recombinamers (ELRs) | es |
dc.subject.classification | vaccine technologies | es |
dc.subject.classification | in vivo immunogenicity | es |
dc.title | A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus | es |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.holder | © 2020 American Chemical Society | es |
dc.identifier.doi | 10.1021/acs.molpharmaceut.0c00054 | es |
dc.relation.publisherversion | https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.0c00054 | es |
dc.identifier.publicationfirstpage | 1608 | es |
dc.identifier.publicationissue | 5 | es |
dc.identifier.publicationlastpage | 1620 | es |
dc.identifier.publicationtitle | Molecular Pharmaceutics | es |
dc.identifier.publicationvolume | 17 | es |
dc.peerreviewed | SI | es |
dc.description.project | Unión Europea-Horizonte 2020 (H2020-NMP-2014-64607) | es |
dc.description.project | Ministerio de Ciencia, Innovación y Universidades (DTS19/00162,MAT2016-79435-R, MAT2016-78903-R, AGL2017-82336-R) | es |
dc.description.project | Comunidad de Madrid (2018/BAA-4370) | es |
dc.description.project | Junta de Castilla y León (VA317P18) | es |
dc.description.project | CIBER-BBN | es |
dc.description.project | Centro en Red de Medicina regenerativa y Terapia celular de Castilla y León | es |
dc.identifier.essn | 1543-8392 | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.type.hasVersion | info:eu-repo/semantics/submittedVersion | es |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
La licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional